Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992825 | 0.86 | CETP (1.00) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL12841121 | 0.85 | CETP (0.73) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL9574421 | 0.83 | CETP (0.51) | CETPL3MBTL1MEN1KMT2ARAB9A | |
| SCHEMBL13212562 | 0.83 | CETP (0.75) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL9746129 | 0.83 | CETP (0.75) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL13212420 | 0.81 | CETP (0.73) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL5706504 | 0.81 | CETP (0.71) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL1534076 | 0.80 | ALDH1A1 (0.55) | CETPPOLBMEN1KMT2ARAB9A | |
| SCHEMBL23987377 | 0.79 | CETP (0.69) | CETPL3MBTL1KDM4EALOX12LMNA | |
| SCHEMBL1534122 | 0.79 | CETP (0.84) | CETPL3MBTL1LMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| EP-2292596-A2 | CETP activity inhibitor | Japan Tobacco, Inc. (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7579379-B2 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20080027109-A1 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-7271196-B2 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TABACCO INC. (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1020439-B1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0336937-B1 | PHOTOGRAPHIC SILVER HALIDE ELEMENT AND PROCESS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1993-10-13 | — | — | EP | disclosed |
| US-5155016-A | Silver halide color photographic material containing novel pyrazoloazole coupler and method to produce color image | FUJI PHOTO FILM CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0336937-A4 | PHOTOGRAPHIC SILVER HALIDE ELEMENT AND PROCESS. | EASTMAN KODAK CO (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0336937-A1 | PHOTOGRAPHIC SILVER HALIDE ELEMENT AND PROCESS. | EASTMAN KODAK CO (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4853319-A | Photographic silver halide element and process | EASTMAN KODAK COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
| WO-1988004795-A1 | PHOTOGRAPHIC SILVER HALIDE ELEMENT AND PROCESS | EASTMAN KODAK COMPANY (US) | 1988-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027109-A1 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | CETP, MTTP, APOB | CETP 1/4885L3MBTL1 1184/4885KDM4E 2520/4885 |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885L3MBTL1 832/4885KDM4E 2930/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885L3MBTL1 501/4885KDM4E 2364/4885 |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | CETP, PCSK9, LCAT | CETP 1/4885L3MBTL1 1808/4885KDM4E 1677/4885 |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | CETP, MTTP, CES1 | CETP 1/4885L3MBTL1 1480/4885KDM4E 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.